Arch Therapeutics Co-Founder Dr. Ellis-Behnke to Speak at Nanomanufacturing Summit 2013 in Philadelphia, October 15, 2013

Arch Therapeutics Co-Founder Dr. Ellis-Behnke to Speak at Nanomanufacturing 
Summit 2013 in Philadelphia, October 15, 2013 
The Company's Development of Medical Devices Manufactured at the
Nanoscale Is Differentiating and Important to Its Future Success 
WELLESLEY, MA -- (Marketwired) -- 10/10/13 --  Arch Therapeutics,
Inc. (OTCQB: ARTH) ("Arch" or the "Company"), is pleased to announce
that co-founding and inventing scientist, Dr. Rutledge Ellis-Behnke,
will be featured during the opening day activities at the
Nanomanufacturing Summit 2013 October 15-17, 2013 at the University
of Pennsylvania in Philadelphia.  
Dr. Ellis-Behnke's keynote speech encompasses, "Nanomedicine:
discovering, manufacturing and using new Molecular Medical Devices
for immediate hemostasis." He will focus on how related new
technology, including AC5(TM), should fundamentally alter the
practice of medicine and surgery, as well as how material design at
the nanoscale can provide desired product properties and
Ellis-Behnke, comments, "The Nanomanufacturing Summit is a great
opportunity for government, universities, industry and business to
exchange emergent information on the current status of nanoscale
products as well as offering insights into new commercial practices
that introduce robust manufacturing techniques with an ability to
actually make the leap from the research lab into medical practices
across the nation and around the world."  
Dr. Ellis-Behnke was instrumental in discovering the hemostatic and
other barrier properties of self-assembling peptides that could make
future surgery and interventional care faster and safer. He proposed
the development and commercialization of what became Arch
Therapeutics' flagship product candidate, now known as AC5(TM). Arch
Therapeutics obtained the exclusive worldwide license on the relevant
intellectual property, of which Dr. Ellis-Behnke is the lead
inventor, from the Massachusetts Institute of Technology and focused
on design and manufacturing at the nanoscale in order to bring
AC5(TM) closer to commercialization.  
Dr. Ellis-Behnke continues, "Arch Therapeutics' work is of vital
importance in this field, as they are instrumental in understanding
how to translate these discoveries into commercially viable processes
and products designed to fulfill areas of extraordinary medical need.
For instance, Arch's focus on surgical bleeding is important because
up to 50% of a surgeon's procedure time can be devoted to controlling
bleeding with the currently available technology."  
Arch Therapeutics CEO, Dr. Terrence Norchi commented, "Dr.
Ellis-Behnke remains a cutting edge thinker in the nanomedicine
realm. He brings an interdisciplinary approach to addressing
challenges of interventional healthcare and healing." Dr. Norchi
further commented, "Our collective focus on product design and build
at the nanoscale is very important to Arch's approach to areas of
significant medical need, starting with the mitigation of bleeding
during surgery. The nanoscale world holds great promise for the
future of medicine and for our products, in particular."  
Additional details regarding Arch Therapeutics, Inc., its business,
agreements and related matters are filed as part of the Company's
continuous public disclosure as a reporting issuer under the
Securities Exchange Act of 1934 filed with the Securities and
Exchange Commission ("SEC"), and are available at the SEC's website
at For more information, visit our website at 
About Arch Therapeutics, Inc. (OTCQB: ARTH)
 Arch Therapeutics, Inc.
(OTCQB: ARTH) is a medical device company developing a novel approach
to stop bleeding (hemostasis) and control leaking (sealant) during
surgery and trauma care. Arch's goal is to develop and commercialize
products based on our innovative technology platform that make
surgery and interventional care faster and safer for patients. Arch's
flagship development stage product candidate known as AC5(TM) is
being designed to elegantly achieve hemostasis in minimally invasive
and open surgical procedures. Find out more at  
Notice Regarding Forward-Looking Statements
 This news release
contains "forward-looking statements" as that term is defined in
Section 27(a) of the Securities Act of 1933, as amended, and Section
21(e) of the Securities Exchange Act of 1934, as amended. Statements
in this press release that are not purely historical are
forward-looking statements and include any statements regarding
beliefs, plans, expectations or intentions regarding the future. Such
forward-looking statements include, among other things, references to
novel technologies and methods, our business and product development
plans and projections, or market information. Actual results could
differ from those projected in any forward-looking statements due to
numerous factors. Such factors include, among others, the inherent
uncertainties associated with developing new products or technologies
and operating as a development stage company, our ability to retain
important members of our management team and attract other qualified
personnel, our ability to raise the additional funding we will need
to continue to pursue our business and product development plans, our
ability to develop and commercialize products based on our technology
platform, and market conditions. These forward-looking statements are
made as of the date of this news release, and we assume no obligation
to update the forward-looking statements, or to update the reasons
why actual results could differ from those projected in the
forward-looking statements. Although we believe that any beliefs,
plans, expectations and intentions contained in this press release
are reasonable, there can be no assurance that any such beliefs,
plans, expectations or intentions will prove to be accurate.
Investors should consult all of the information set forth herein and
should also refer to the risk factors disclosure outlined in the
reports and other documents we file with the SEC, available at 
On Behalf of the Board, 
Terrence W. Norchi, MD.
 Arch Therapeutics, Inc. 
ARTH Investor Relations
Toll Free: +1-855-340-ARTH (2784) (US and Canada)
Press spacebar to pause and continue. Press esc to stop.